Peripheral neuropathy in transgenic diabetic mice - Restoration of C-fiber function with human recombinant nerve growth factor

被引:48
|
作者
Elias, KA
Cronin, MJ
Stewart, TA
Carlsen, RC
机构
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Univ Calif Davis, Sch Med, Dept Human Physiol, Davis, CA USA
关键词
D O I
10.2337/diabetes.47.10.1637
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mice (Ins.D(d)1) with hypoinsulinemic diabetes were created by increased expression of syngeneic major histocompatibility complex (MHC) class I protein in pancreatic beta-cells. The diabetic state was characterized in these mice by high glucose concentrations and islet pathology. To determine whether a neuropathy would develop, motor and sensory conduction velocities (CV) were determined in the sciatic nerves of 2-, 4-, and 7-month-old control and diabetic littermate male mice. Recording bipolar electrodes were placed in the plantar muscles of the hind foot of anesthetized (ketamine/xylazine) mice. Bipolar stimulating electrodes mere positioned near the sciatic nerve at the sciatic notch or near the tibial nerve at the ankle. Motor CV from cu-motor fibers and sensory CV from proprioceptive Aa nerves were measured and expressed as meters per second (m/s). Group data are reported as mean +/- SE and compared by analysis of variance. The CVs from nondiabetic mice (controls) were not different across the three ages and averaged 41.3 +/- 1.7 m/s for motor and 38.7 +/- 1.7 m/s for sensory. The motor CVs from diabetic mice at 2 and 4 months were similar to controls. Sensory CVs were unchanged at 2 months but were lower at 4 months (18.9 +/- 2.4 m/s). Both sensory (23.9 +/- 2.1 m/s) and motor (18.9 +/- 1.8 m/s) CVs were significantly reduced at 7 months, which is indicative of a polyneuropathy. NGF has well-known trophic effects on sympathetic and small sensory neurons. To determine whether NGF could influence this neuropathy, 6-month-old control and diabetic mice were divided into the following groups: 1) control + vehicle, 2) diabetic + vehicle, and 3) diabetic + NGF (1 mg/kg, 3 x week, s.c.). After 1 month of treatment, motor and sensory CVs were determined. In some mice, the branches of the sciatic nerve were exposed and in situ recordings from the sural nerve were performed to determine compound C-fiber CV, integral, and amplitude. Sensory CV, determined via Hoffmann's reflex (H-reflex) (A-fiber), was decreased in diabetic compared with control animals as expected (P < 0.05), and NGF did not alter this parameter. Continuing diabetes reduced the amplitude (0.9 +/- 0.2 vs. 3.2 +/- 0.7 mV x 10(-2); P < 0.05) and integral (6.9 +/- 1.9 mV/ms vs. 18.8 +/- 4,4 mV/ms; P < 0.05) of the C-fiber response versus control, suggesting fiber loss. NGF treatment normalized C-fiber amplitude (2.9 +/- 0.8 mV x 10(-2)) and integral(21.2 +/- 6.5 mV/ms) in animals with established diabetes, with no effect on blood glucose. The C-fiber CV was similar in all groups, indicating that the animals had some normally conducting small fiber sensory nerves. These studies characterized a motor and sensory polyneuropathy in transgenic diabetic mice and are the first to demonstrate directly that NGF treatment can protect or restore abnormal sensory C-fiber function.
引用
收藏
页码:1637 / 1642
页数:6
相关论文
共 50 条
  • [1] Human studies of recombinant human nerve growth factor and diabetic peripheral neuropathy
    Freeman, R
    EUROPEAN NEUROLOGY, 1999, 41 : 20 - 26
  • [2] Evaluation of nociceptive C-fiber function in diabetic peripheral neuropathy
    Berghoff, M
    Kilo, S
    Hilz, MJ
    Freeman, R
    NEUROLOGY, 2002, 58 (07) : A345 - A345
  • [3] Microvascular and C-fiber function in diabetic Charcot neuroarthropathy and diabetic peripheral neuropathy
    Baker, Neil
    Green, Alistair
    Krishnan, Singhan
    Rayman, Gerry
    DIABETES CARE, 2007, 30 (12) : 3077 - 3079
  • [4] Peripheral nerve function in diabetic small fiber neuropathy
    Gibbons, Christopher
    Centi, Justin
    Freeman, Roy
    NEUROLOGY, 2008, 70 (11) : A126 - A126
  • [5] CLINICAL-TRIAL OF RECOMBINANT HUMAN NERVE GROWTH-FACTOR (RHNGF) IN PERIPHERAL NEUROPATHY
    APFEL, S
    ADORNATO, B
    CORNBLATH, D
    KESSLER, J
    PETTY, B
    CHAUDHRY, V
    SCHWARTZ, S
    RASK, C
    NEUROLOGY, 1995, 45 (04) : A278 - A279
  • [6] Recombinant human nerve growth factor and diabetic polyneuropathy
    Zochodne, DW
    Said, G
    NEUROLOGY, 1998, 51 (03) : 662 - 663
  • [7] Utility of Measures of Nerve Fiber Function and Structure for the Diagnosis of Diabetic Peripheral Neuropathy
    Casellini, Carolina M.
    Parson, Henri
    Cushman, Courtny
    Ingram, Amber M.
    Pettaway, Jordan L.
    Sears, Taneisha
    Siraj, Elias S.
    DIABETES, 2023, 72
  • [8] The role of endogenous nerve growth factor in human diabetic neuropathy
    Anand, P
    Terenghi, G
    Warner, G
    Kopelman, P
    WilliamsChestnut, RE
    Sinicropi, DV
    NATURE MEDICINE, 1996, 2 (06) : 703 - 707
  • [9] Investigating C-Fiber Activation and Pain Sensitivity in Diabetic Sensorimotor Neuropathy with Transcutaneous Electrical Nerve Stimulation
    Eldesouky, Omar
    Seebauer, Lukas
    Rukwied, Roman
    Carr, Richard
    Roshan, Mani
    Sulaj, Alba
    Tsilingiris, Dimitrios
    Kopf, Stefan
    Fleming, Thomas H.
    Schmelz, Martin
    Szendroedi, Julia
    Kender, Zoltan
    DIABETES, 2024, 73
  • [10] Altered C-Fiber Function as an Indicator of Early Peripheral Neuropathy in Individuals With Impaired Glucose Tolerance
    Green, Alistair Q.
    Krishnan, Singhan
    Finucane, Francis M.
    Rayman, Gerry
    DIABETES CARE, 2010, 33 (01) : 174 - 176